On January 19, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it had received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum closing bid price requirement. The company's stock had closed below the $1.00 minimum bid price for 30 consecutive business days. Despite the notice, Apollomics' shares continue to be listed and traded on the Nasdaq Capital Market under the ticker symbol 'APLM'. The company has been granted a 180-day period, until July 15, 2024, to regain compliance with the bid price requirement. If Apollomics fails to meet the requirement within this timeframe, it may be eligible for an additional 180 days to achieve compliance, potentially through a reverse stock split. The company is actively monitoring its stock price and considering options to address the deficiency, but there is no guarantee of regaining or maintaining compliance with Nasdaq's listing requirements.

On January 19, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that it had received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum closing bid price requirement. The company's stock had closed below the $1.00 minimum bid price for 30 consecutive business days. Despite the notice, Apollomics' shares continue to be listed and traded on the Nasdaq Capital Market under the ticker symbol 'APLM'. The company has been granted a 180-day period, until July 15, 2024, to regain compliance with the bid price requirement. If Apollomics fails to meet the requirement within this timeframe, it may be eligible for an additional 180 days to achieve compliance, potentially through a reverse stock split. The company is actively monitoring its stock price and considering options to address the deficiency, but there is no guarantee of regaining or maintaining compliance with Nasdaq's listing requirements.